33 新規抗腫瘍性抗生物質C-1027のクロモフォアの構造(口頭発表の部)
スポンサーリンク
概要
- 論文の詳細を見る
Antibiotic C-1027, a novel antitumor chromoprotein isolated from the broth filtrate of Streptomyces globisporus C-1027, shows extremely potent cytotoxicity against KB carcinoma cells (IC_<50> 0.1ng/ml) in vitro and antitumor activity toward tumor-bearing mice in vivo. These activities are correlated with the ability of the antibiotic to cause DNA double-strand scission. The antibiotic consists of an apoprotein and a labile chromophore (C-1027-Chr) that is responsible for the biological activity of C-1027. The chromophore is readily separated from its apo-protein by extraction, but the exceeding instability in the protein-free state hampered the structure elucidation. The similar situation has been also observed in the other chromoprotein antibiotics of this family such as neocarzinostatin (NCS), macromomycin, auromomycin (AUR), actinoxanthin and kedarcidin. Among them, NCS is the only one whose chromophore structure has been elucidated, and very recently, the structural novelty of kedarcidin chromophore has been disclosed by the Bristol-Myers Squibb group. We have characterized an inactive but more stable reaction product (2) of C-1027-Chr, which was prepared by treatment of C-1027-Chr in ethanol. It possesses a macrocyclic structure together with oxazolinate and aminosugar moieties as side chains. Its benzodihydropentalene core structure suggested to us the presence of an enediyne in the native C-1027-Chr. We disclose herein the novel structure of C-1027-Chr (1) and the cycloaromatization mechanism leading to product (2), which would explain its extreme potency in terms of cytotoxicity and ability to cause DNA double-strand scission.
- 天然有機化合物討論会の論文
- 1993-09-10
著者
-
吉田 健一郎
Tokushima Institute Taiho Pharmaceutical Co. Ltd.
-
吉田 健一郎
大鵬薬品代謝分析研
-
東 龍太郎
大鵬薬品代謝分析研
-
佐伯 真由子
大鵬薬品代謝分析研
-
南 慶典
大鵬薬品代謝分析研
-
大谷 敏夫
大鵬薬品化学療法剤研
-
南 慶典
Tokushima Institute, Taiho Pharmaceutical Co., Ltd.,
-
南 慶典
Tokushima Institute Taiho Pharmaceutical Co. Ltd.
-
大谷 敏夫
大鵬薬品
-
佐伯 真由子
大鵬薬品工業(株) 代謝分析研究所
関連論文
- 33 新規抗腫瘍性抗生物質C-1027のクロモフォアの構造(口頭発表の部)
- Antitumor Agents. II : Regio- and Stereospecific Syntheses of 1-β-Alkyl-1-desoxypodophyllotoxin Derivatives and Biological Activity
- Alkaline and Neutral Degradation of Cefodizime (THR-221) and Structural Elucidation of the Products. II.
- Acidic Degradation of Cefodizime (THR-221) and Structural Elucidation of the Products. I
- Degradation of β-Lactamase Inhibitor (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H) in the Solid State : Structural Elucidation
- Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
- Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
- Degradation of β-Lactamase Inhibitor, (2S, 3R, 5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H), in Aqueous Solutions and Alkaline Methanol Solution : Pathway and Structural Elu
- 新規抗悪性腫瘍薬 S-1 の各配合成分の体内動態 (第6報) : ラットにおける S-1 の各配合成分の代謝
- 32 新規テロメラーゼ阻害物質telomestatinに関する研究(口頭発表の部)
- 44(P-3) 超天然物の設計と創製 : 抗腫瘍性抗生物質C-1027の合理的改変による安定化(ポスター発表の部)
- 56(P-29) 抗腫瘍性抗生物質C-1027の三次元構造(ポスター発表の部)
- 39 クロモプロテイン系エンジイン抗生物質の化学 : 常磁性を示す原理(口頭発表の部)
- 門脈 - 体循環血濃度差法によるイヌ小腸及び肝の初回通過効果
- 新規抗心不全薬MET-88の体内動態(3) - ラットにおける新代謝経路について -
- Tannins and Related Compounds. LXXXV. : Structures of Novel C-Glycosidic Ellagitannins, Grandinin and Pterocarinins A and B
- クリアランスモデルに基づいた TAS-102 経口投与時の FTD 体内動態の予測 : ラット, サルからヒトへ
- TAS-102経口投与におけるヒトFTD代謝の予測